Sol-Gel Technologies Ltd. (SLGL) Company Gross Revenue

Sol-Gel Technologies (SLGL) commercial revenue levels demonstrate the impact of stringent FDA standards and microencapsulation patent protections, where 0.00 serves as the base parameter value. Demand for dermatological products remains stable regardless of economic conditions. Business income is based on royalty payments, while major distributors manage final pricing.

SLGL Sol-Gel Technologies, Ltd.: Company Revenue in the range 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Sol-Gel Technologies Ltd. (SLGL)

- current price and projected stock value:

Share Price Sol-Gel Technologies, Ltd.|SLGL - Price Target Chart

- market capitalization details:

Market Capitalization Sol-Gel Technologies Ltd.|SLGL - Total Company Value

- book capitalization data:

Net Asset Value per Share Sol-Gel Technologies|SLGL - Company Book Value|Market Value to Book Value Ratio sol-gel.com|SLGL - Cumulative Company Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

SLGL - Net Income|Future Net Profit Sol-Gel Technologies|SLGL - P/E Multiple|Projected Price to Earnings Ratio sol-gel.com|SLGL - PEG Multiple|Enterprise Value to EBITDA Ratio Sol-Gel Technologies Ltd.|SLGL - Operating profit EBITDA|Earnings per share for the trailing year Sol-Gel Technologies|SLGL - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months sol-gel.com|SLGL - Earnings per share growth in current year|Expected net earnings per share growth next year Sol-Gel Technologies

- sales volume and revenue indicators:

SLGL - Company Revenue|Company Projected Revenue Sol-Gel Technologies, Ltd.|SLGL - Price-to-Revenue Ratio|Market Cap to Future Revenue Ratio Sol-Gel Technologies Ltd.

Summary company analysis:SLGL (Sol-Gel Technologies, Ltd.)

Mass-produced product of Sol-Gel Technologies Ltd.

An investment audit of Sol-Gel Technologies (SLGL) requires a precise assessment of cash flow dynamics before entering the asset. This indicator aggregates all operating revenues from product sales, measuring the actual speed of liquidity generation. For this pharmaceutical leader in transdermal delivery, it confirms the commercial success of innovations and physician trust. Analyzing the company's commercial revenue allows for the timely recognition of demand stagnation and helps avoid buying at the peak.

Analysis of competing companies